GMDA - Gamida Cell Ltd.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
4.0800
-0.1000 (-2.39%)
As of 1:44PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close4.1800
Open4.1800
Bid4.0600 x 1000
Ask4.1700 x 900
Day's Range4.0700 - 4.1900
52 Week Range2.9300 - 15.4100
Volume2,039
Avg. Volume33,450
Market Cap104.474M
Beta (3Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-3.2030
Earnings DateNov 5, 2019 - Nov 11, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est18.00
Trade prices are not sourced from all markets
  • Business Wire

    Gamida Cell and the CIBMTR Announce Collaboration to Advance Research for Life-Saving Cellular Therapy

    Gamida Cell Ltd. (GMDA), a leading cellular and immune therapeutics company, and the CIBMTR® (Center for International Blood and Marrow Transplant Research®) today announced the entry into a research agreement to collect and analyze health outcomes data in patients with hematologic malignancies who receive an allogeneic hematopoietic stem cell transplant (HSCT, or bone marrow transplant) from various donor sources. The CIBMTR is an organization that collaborates with the global scientific community to advance hematopoietic cell transplantation (HCT) and cellular therapy worldwide.

  • Could Gamida Cell Ltd.'s (NASDAQ:GMDA) Investor Composition Influence The Stock Price?
    Simply Wall St.

    Could Gamida Cell Ltd.'s (NASDAQ:GMDA) Investor Composition Influence The Stock Price?

    Every investor in Gamida Cell Ltd. (NASDAQ:GMDA) should be aware of the most powerful shareholder groups. Insiders...

  • Gamida Cell Enters Oversold Territory
    Zacks

    Gamida Cell Enters Oversold Territory

    Gamida Cell has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.

  • Business Wire

    Gamida Cell Reports Second Quarter 2019 Financial Results and Provides Company Update

    – Successfully completed follow-on public offering raising approximately $40 million in gross proceeds –

  • Business Wire

    Gamida Cell Announces Pricing of $35 Million Public Offering of Ordinary Shares

    Gamida Cell Ltd. (GMDA), a leading cellular and immune therapeutics company, today announced the pricing of an underwritten public offering of 7,000,000 ordinary shares at a public offering price of $5.00 per share for aggregate gross proceeds of $35 million, before deducting underwriting discounts and commission and estimated offering expenses. In addition, Gamida Cell has granted the underwriters a 30-day option to purchase up to an additional 1,050,000 ordinary shares at the public offering price, less the underwriting discounts and commissions. RBC Capital Markets and JMP Securities are acting as joint book-running managers for this offering.

  • GlobeNewswire

    ELBIT IMAGING ANNOUNCES THAT GAMIDA CELL ANNOUNCES LAUNCH OF PROPOSED PUBLIC OFFERING OF ORDINARY SHARES

    Tel Aviv, Israel, June 25, 2019 (GLOBE NEWSWIRE) --  Elbit Imaging Ltd. (TASE, UTC UC: EMITF) (“Elbit” or the “Company”) announced today that on June 24, 2019, Gamida Cell Ltd. (GMDA) (“Gamida”), an indirect shareholding of the Company announced the launch of a proposed follow-on public offering of approximately $30.0 million of its ordinary shares (approximately 4.04 million shares). In addition, Gamida Cell expects to grant the underwriters a 30-day option to purchase up to $4.5 million of additional ordinary shares (up to 606,000 shares) at the public offering price, less underwriting discounts and commissions. RBC Capital Markets and JMP Securities are acting as joint book-running managers for this offering.

  • Business Wire

    Gamida Cell Announces Launch of Proposed Public Offering of Ordinary Shares

    Gamida Cell Ltd. (GMDA), a leading cellular and immune therapeutics company, today announced the launch of a proposed follow-on public offering of approximately $30.0 million of its ordinary shares. In addition, Gamida Cell expects to grant the underwriters a 30-day option to purchase up to $4.5 million of additional ordinary shares at the public offering price, less underwriting discounts and commissions. RBC Capital Markets and JMP Securities are acting as joint book-running managers for this offering.

  • Business Wire

    Gamida Cell and Lonza Establish Commercial Manufacturing Agreement for Omidubicel

    Gamida Cell Ltd. (GMDA), a leading cellular and immune therapeutics company, and Lonza (LONN.SW), an integrated healthcare solutions provider, today announced that the companies have entered into a strategic manufacturing agreement. The agreement provides for the future commercial production after potential FDA approval of omidubicel, Gamida Cell’s investigational advanced cell therapy currently in clinical development designed to enhance the life-saving benefits of hematopoietic stem cell (bone marrow) transplant. This agreement follows a successful multi-year clinical manufacturing relationship and provides Gamida Cell with a path to commercial supply of omidubicel.

  • Business Wire

    Gamida Cell Bolsters Management Team with Appointment of Tracey Lodie, Ph.D., as Chief Scientific Officer

    Gamida Cell Ltd. (GMDA), a leading cellular and immune therapeutics company, today announced the appointment of Tracey Lodie, Ph.D., as chief scientific officer. Dr. Lodie will be responsible for setting the scientific strategy, synthetic biology and priorities for Gamida Cell, as well as overseeing translational research for our clinical pipeline. “We are delighted to welcome Tracey to Gamida Cell.

  • Business Wire

    Gamida Cell Announces Data for Omidubicel Presented at the International Society for Cellular and Gene Therapy 2019 Annual Meeting

    Gamida Cell Ltd. (GMDA), a leading cellular and immune therapeutics company, today announced that two presentations on omidubicel1 (formerly known as NiCord®), an investigational advanced cell therapy in Phase 3 clinical development designed to enhance the life-saving benefits of hematopoietic stem cell (bone marrow) transplant, took place at the International Society for Cell and Gene Therapy (ISCT) 2019 Annual Meeting being held in Melbourne, Australia. The presentations included a summary of clinical and translational data from the completed Phase 1/2 clinical study of omidubicel in patients with high-risk hematologic malignancies, or blood cancers.

  • Business Wire

    Gamida Cell to Hold Annual Meeting of Stockholders

    Gamida Cell Ltd. , a leading cellular and immune therapeutics company, today announced that its previously scheduled Annual Meeting of Stockholders will be webcast on Tuesday, June 4, 2019, at 10:00 a.m.

  • Business Wire

    Gamida Cell to Participate in Two Upcoming Healthcare Conferences in New York City

    Gamida Cell Ltd. , a leading cellular and immune therapeutics company, today announced that the company will participate in two upcoming healthcare conferences taking place in New York City during May.

  • Associated Press

    Gamida Cell: 1Q Earnings Snapshot

    On a per-share basis, the Jerusalem-based company said it had a loss of 62 cents. Gamida Cell shares have dropped 27% since the beginning of the year. _____ This story was generated by Automated Insights ...

  • Business Wire

    Gamida Cell Reports First Quarter 2019 Financial Results and Provides Company Update

    – Announces USAN selection of omidubicel as nonproprietary name for company’s investigational NAM-expanded hematopoietic stem cells –

  • Business Wire

    Gamida Cell Announces the Date of Its First Quarter 2019 Financial Results and Webcast

    Gamida Cell Ltd. , a leading cellular and immune therapeutics company, today announced that the company will host a conference call and live audio webcast on Tuesday, May 7, 2019, at 8:30 a.m.

  • Business Wire

    Gamida Cell to Present at the Solebury Trout Class of 2018 Biotech IPOs Investor Day

    Gamida Cell Ltd. , a leading cellular and immune therapeutics company, today announced that Julian Adams, Ph.D., the company’s chief executive officer, will present an overview of the company at the Solebury Trout Class of 2018 Biotech IPOs Investor Day on Friday, April 26, 2019, at 2:30 p.m.

  • Business Wire

    Gamida Cell to Present at the 18th Annual Needham Healthcare Conference

    Gamida Cell Ltd. , a leading cellular and immune therapeutics company, today announced that Julian Adams, Ph.D., the company’s chief executive officer, will present an overview of the company at the 18th Annual Needham Healthcare Conference on Tuesday, April 9, 2019, at 10:40 a.m.

  • Business Wire

    Gamida Cell Nominates Two Healthcare Industry Veterans to Its Board of Directors

    Gamida Cell Ltd. (GMDA), a leading cellular and immune therapeutics company, today announced the nominations of Shawn Cline Tomasello and Stephen T. Wills to its board of directors. If elected, Ms. Tomasello will join the compensation committee, and Mr. Wills will join the company’s audit committee, bringing commercial, operational and financial experience to Gamida Cell’s board of directors as the company advances its clinical development candidates: NiCord®, an investigational advanced cell therapy in Phase 3 clinical development designed to enhance and expand the life-saving benefits of hematopoietic stem cell (bone marrow) transplant, and NAM-NK, an investigational, cell-based cancer immunotherapy in Phase 1 development in patients with non-Hodgkin lymphoma and multiple myeloma.

  • Gamida Cell Sees Hammer Chart Pattern: Time to Buy?
    Zacks

    Gamida Cell Sees Hammer Chart Pattern: Time to Buy?

    Gamida Cell Ltd. (GMDA) has been struggling lately, but the selling pressure may be coming to an end soon.

  • Business Wire

    Gamida Cell Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Company Update

    – Successfully Completed IPO Raising $53.2 Million in Gross Proceeds –

  • Business Wire

    Gamida Cell Announces Immune Reconstitution Data from Completed Phase 1/2 Clinical Study of NiCord® Presented at 2019 TCT Annual Meeting

    Gamida Cell Ltd. (GMDA), a leading cellular and immune therapeutics company, today announced that translational data from the completed Phase 1/2 clinical study of NiCord® were reported in an oral presentation at the 2019 Transplantation & Cellular Therapy (TCT) Meetings of American Society for Blood and Marrow Transplantation (ASBMT) and Center for International Blood and Marrow Transplant Research (CIBMTR) in Houston, Texas. The data demonstrated that treatment with NiCord, an investigational advanced cell therapy designed to enhance and expand the life-saving benefits of bone marrow transplant for patients with hematologic malignancies, resulted in rapid and robust immune reconstitution. “Reconstitution of a patient’s bone marrow and immune system is a crucial factor in recovery following allogeneic hematopoietic stem cell transplant,” said Jaap-Jan Boelens, M.D., Ph.D., Chief, Pediatric Stem Cell Transplantation and Cellular Therapies Service, Memorial Sloan Kettering Cancer Center.

  • Business Wire

    Gamida Cell Presents New Data from Ongoing Phase 1 Study of NAM-NK and Initial Data from Phase 1/2 Study of NiCord® in Severe Aplastic Anemia at 2019 TCT Annual Meeting

    Gamida Cell Ltd. (GMDA), a leading cellular and immune therapeutics company, today announced that new data from its NAM-NK and NiCord® programs was presented at the 2019 Transplantation & Cellular Therapy (TCT) Meetings of American Society for Blood and Marrow Transplantation and Center for International Blood and Marrow Transplant Research taking place in Houston, Texas. Data reported from the first 14 patients in the ongoing Phase 1 study of NAM-NK, an investigational, cell-based cancer immunotherapy, in patients with non-Hodgkin lymphoma (NHL) and multiple myeloma (MM) demonstrated that NAM-NK was highly active, with three complete responses observed in patients with NHL and one complete response in a patient with MM.

  • Business Wire

    Gamida Cell Announces Agreement with Editas Medicine to Evaluate Use of CRISPR Genome Editing Technology in NAM-NK Cells

    Gamida Cell Ltd. (GMDA), a leading cellular and immune therapeutics company, today announced an agreement with Editas Medicine, Inc., a leading genome editing company, to evaluate the potential use of Editas Medicine’s CRISPR technology to edit NAM-NK cells, which are natural killer cells that have been expanded using Gamida Cell’s proprietary nicotinamide-based, or NAM, technology. Through this agreement, the companies aim to discover optimized NAM-NK cells that could be used to improve the treatment of hematologic malignancies (blood cancers) and solid tumors. “We are encouraged by the early data generated in the Phase 1 study of NAM-NK as an investigational therapy for patients with non-Hodgkin lymphoma and multiple myeloma, and we are pleased to have the opportunity to accelerate and broaden our NAM-NK research efforts through this agreement,” stated Julian Adams, Ph.D., chief executive officer of Gamida Cell.